Cancer Cachexia: Mechanisms and Clinical Implications
暂无分享,去创建一个
[1] O. Ukkola. [Cachexia]. , 2020, Duodecim; laaketieteellinen aikakauskirja.
[2] V. Ruíz García,et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. , 2013, The Cochrane database of systematic reviews.
[3] F. Bozzetti. Basics in Clinical Nutrition: Nutritional support in cancer , 2010 .
[4] C. Loprinzi,et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). , 2010, Lung cancer.
[5] S. Anker,et al. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference , 2010, Expert opinion on investigational drugs.
[6] M. DeBoer. Update on melanocortin interventions for cachexia: progress toward clinical application. , 2010, Nutrition.
[7] P. Contu,et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. , 2010, The oncologist.
[8] K. Fox,et al. Estimation of Cachexia among Cancer Patients Based on Four Definitions , 2009, Journal of oncology.
[9] D. McMillan. Systemic inflammation, nutritional status and survival in patients with cancer , 2009, Current opinion in clinical nutrition and metabolic care.
[10] M. Tisdale. Mechanisms of cancer cachexia. , 2009, Physiological reviews.
[11] S. Paterson-Brown,et al. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer , 2009, British Journal of Cancer.
[12] P. Ponikowski,et al. Cachexia: a new definition. , 2008, Clinical nutrition.
[13] G. Lynch,et al. The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. , 2008, Pharmacology & therapeutics.
[14] F. Strasser. Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue , 2008, Current opinion in clinical nutrition and metabolic care.
[15] D. McMillan,et al. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer , 2008, Proceedings of the Nutrition Society.
[16] P. Contu,et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. , 2008, Nutrition.
[17] H. Friess,et al. Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.
[18] Keith W. Whitaker,et al. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1β administration , 2008, Neuropharmacology.
[19] L. Kachnic,et al. A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122) , 2008, Supportive Care in Cancer.
[20] Georg Endler,et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.
[21] C. Dejong,et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? , 2007, Clinical nutrition.
[22] D. Alberts,et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.
[23] I. Bosaeus,et al. Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia , 2007, Clinical Cancer Research.
[24] P. Novotny,et al. A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome , 2007, Cancer.
[25] G. Filippatos,et al. Is There a Human Homologue to the Murine Proteolysis-Inducing Factor? , 2007, Clinical Cancer Research.
[26] A. Rossi,et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. , 2007, The Lancet. Oncology.
[27] R. Skipworth,et al. Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. , 2007, Journal of pain and symptom management.
[28] D. Marks,et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. , 2007, Endocrinology.
[29] I. Bosaeus,et al. Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning , 2007, Clinical Cancer Research.
[30] P. Beale,et al. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial , 2007, Supportive Care in Cancer.
[31] B. Higgins,et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. , 2007, The Cochrane database of systematic reviews.
[32] S. Paterson-Brown,et al. Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer , 2006, British Journal of Cancer.
[33] E. Bruera,et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. , 2006, The American journal of clinical nutrition.
[34] F. Strasser,et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] K. Fritsche. Fatty acids as modulators of the immune response. , 2006, Annual review of nutrition.
[36] K. Fearon,et al. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.
[37] M. Muscaritoli,et al. IGF-1 is downregulated in experimental cancer cachexia. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[38] G. Bodoky,et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. , 2006, Clinical nutrition.
[39] C. Dejong,et al. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. , 2005, The international journal of biochemistry & cell biology.
[40] N. Christakis,et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Helmut Friess,et al. Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia , 2005, Clinical Cancer Research.
[42] P. Ravasco,et al. Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy , 2005, Head & neck.
[43] Patrick Schrauwen,et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. , 2005, Oncology reports.
[44] Brock T Brown,et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. , 2005, Endocrinology.
[45] S. Paterson-Brown,et al. Serum parathyroid hormone‐related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma , 2005, Cancer.
[46] S. Wigmore,et al. Systemic inflammation, cachexia and prognosis in patients with cancer , 2005, Current opinion in clinical nutrition and metabolic care.
[47] P. Goggin,et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial , 2005, Gut.
[48] P. Ravasco,et al. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Jen,et al. Characterization of a Human Homologue of Proteolysis-Inducing Factor and Its Role in Cancer Cachexia , 2004, Clinical Cancer Research.
[50] D. Krieger,et al. Correlation Between Ammonia Levels and the Severity of Hepatic Encephalopathy , 2004 .
[51] Max Dahele,et al. Research methodology: cancer cachexia syndrome , 2004, Palliative medicine.
[52] A. Asakawa,et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides , 2004, Current opinion in clinical nutrition and metabolic care.
[53] P. Novotny,et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] M. Herdman,et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. , 2004, Journal of pain and symptom management.
[55] Paula Ravasco,et al. Cancer: disease and nutrition are key determinants of patients’ quality of life , 2004, Supportive Care in Cancer.
[56] K. Fearon,et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.
[57] I. Bosaeus,et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. , 2004, International journal of oncology.
[58] N. Aaronson,et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.
[59] M. Tisdale,et al. Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB , 2003, British Journal of Cancer.
[60] N. Macdonald,et al. Understanding and managing cancer cachexia. , 2003, Journal of the American College of Surgeons.
[61] C. McArdle,et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. , 2003, Lung cancer.
[62] F. López‐Soriano,et al. Cancer cachexia: the molecular mechanisms. , 2003, The international journal of biochemistry & cell biology.
[63] Tim Cheetham,et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. , 2003, The New England journal of medicine.
[64] P. Goggin,et al. Thalidomide and its derivatives: emerging from the wilderness , 2003, Postgraduate medical journal.
[65] B. Glimelius,et al. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. , 2002, Anticancer research.
[66] G. Biolo,et al. Regulation of muscle cathepsin B proteolytic activity in protein-depleted patients with chronic diseases. , 2002, Clinical nutrition.
[67] T. Zimmers,et al. Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.
[68] P. Lissoni. Is there a role for melatonin in supportive care? , 2002, Supportive Care in Cancer.
[69] P. Novotny,et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] P. Dagnelie,et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] D. Ferrigno,et al. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. , 2001, Lung cancer.
[72] J. Kamegai,et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. , 2001, Diabetes.
[73] D. Chinkes,et al. Reversal of catabolism by beta-blockade after severe burns. , 2001, The New England journal of medicine.
[74] T. Lipman,et al. AGA technical review on parenteral nutrition. , 2001, Gastroenterology.
[75] M. Tisdale,et al. Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF) , 2001, British Journal of Cancer.
[76] I. Waddell,et al. Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[77] R. Cone,et al. Role of the central melanocortin system in cachexia. , 2001, Cancer research.
[78] M. Nakazato,et al. A role for ghrelin in the central regulation of feeding , 2001, Nature.
[79] S. Meijsing,et al. Cancer cachexia: A therapeutic approach , 2001, Medicinal research reviews.
[80] M. Tisdale,et al. Effect of the specific cyclooxygenase‐2 inhibitor meloxicam on tumour growth and cachexia in a murine model , 2000, International journal of cancer.
[81] C. Garcı́a-Martı́nez,et al. Calpain-3 gene expression is decreased during experimental cancer cachexia. , 2000, Biochimica et biophysica acta.
[82] C. McArdle,et al. Prognostic Factors in Advanced Gastrointestinal Cancer Patients With Weight Loss , 2000, Nutrition and cancer.
[83] J. Ross,et al. Effect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer , 2000, Nutrition and cancer.
[84] K. Lundholm,et al. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. , 2000, European journal of cancer.
[85] P. Novotny,et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] K. Fearon,et al. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. , 1999, International journal of oncology.
[87] A. Inui,et al. Cancer anorexia-cachexia syndrome: are neuropeptides the key? , 1999, Cancer research.
[88] K. Fearon,et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer , 1999, British Journal of Cancer.
[89] L. Mariani,et al. Artificial Nutrition in Cancer Patients: Which Route, What Composition? , 1999, World Journal of Surgery.
[90] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[91] M. Tisdale,et al. Catabolism of adipose tissue by a tumour‐produced lipid‐mobilising factor , 1999, International journal of cancer.
[92] M. Tisdale,et al. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. , 1998, Cancer research.
[93] M. Tisdale,et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. , 1998, Cancer research.
[94] M. Tisdale,et al. Purification and characterization of a tumor lipid-mobilizing factor. , 1998, Cancer research.
[95] A. Norman,et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? , 1998, European journal of cancer.
[96] R. Seeley,et al. Melanocortin receptors in leptin effects , 1997, Nature.
[97] V. Rivera,et al. Transcriptional squelching re-examined , 1997, Nature.
[98] E. Bruera. ABC of palliative care: Anorexia, cachexia, and nutrition , 1997 .
[99] G. Barsh,et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.
[100] S. Barni,et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state , 1997, Journal of pineal research.
[101] G. Mantovani,et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. , 1997, European journal of cancer.
[102] J. Fischer,et al. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y , 1996, Peptides.
[103] K. Fearon,et al. Characterization of a cancer cachectic factor , 1996, Nature.
[104] J. O'fallon,et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] J. Ross,et al. Acute‐phase protein response and survival duration of patients with pancreatic cancer , 1995, Cancer.
[106] K. Yasumoto,et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. , 1995, Cancer research.
[107] P. Reeds,et al. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? , 1994, The Journal of nutrition.
[108] D. McMillan,et al. Protein synthesis in cancer patients with inflammatory response: investigations with [15N]glycine. , 1994, Nutrition.
[109] J. Ross,et al. Cytokines, the Acute‐Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic Cancer , 1994, Annals of surgery.
[110] M. Papa,et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.
[111] G. Kaplan,et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.
[112] G. Strassmann,et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.
[113] D. Schaid,et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia , 1990, Cancer.
[114] S. Jonjić,et al. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.
[115] J. Norton,et al. Body cell mass in cancer-bearing and anorexic patients. , 1987, JPEN. Journal of parenteral and enteral nutrition.
[116] R. Chlebowski,et al. Influence of nandrolone decanoate on weight loss in advanced non‐small cell lung cancer , 1986, Cancer.
[117] R. Makuch,et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. , 1985, Cancer research.
[118] E. Bruera,et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. , 1985, Cancer treatment reports.
[119] K. Calman,et al. Prednisolone as an appetite stimulant in patients with cancer. , 1984, British medical journal.
[120] C. Begg,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[121] Joseph R. Bertino,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[122] R. Hahn,et al. Corticosteroid therapy of preterminal gastrointestinal cancer , 1974, Cancer.
[123] M. Muscaritoli,et al. New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. , 2008, Asia Pacific journal of clinical nutrition.
[124] M. Guarcello,et al. EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life , 2007 .
[125] P. Loehrer. Comparison of Orally Administered Cannabis Extract and Delta-9 Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group , 2007 .
[126] M. Elia,et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. , 2006, International journal of oncology.
[127] Z. Ortiz,et al. Megestrol acetate for the treatment of anorexia-cachexia syndrome. , 2005, The Cochrane database of systematic reviews.
[128] Rocco Barazzoni,et al. Metabolic consequences of physical inactivity. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[129] E. Bruera,et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] C. McArdle,et al. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. , 1999, Nutrition and cancer.
[131] K. Fearon,et al. Cancer cachexia. , 1999, Surgical oncology.
[132] D. Heber,et al. Clinical aspects of nutrition in advanced cancer. , 1992, Oncology.
[133] G. Opdenakker,et al. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.
[134] K. Lundholm,et al. Elevated energy expenditure in cancer patients with solid tumours. , 1991, European journal of cancer.
[135] L. Moldawer,et al. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. , 1991, Cancer research.